Document text
Principal Investigator: ELLIS L REINHERZ
Organization: DANA-FARBER CANCER INST
Fiscal Year: 2024
Award: $102,537
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY – CORE A
The Administrative Core A is requested to facilitate internal interactions among PIs of Projects 1-2, leaders of
the four technology components, Core B (Antibody Neutralization), and the IAVI Biobank at both on- and off-
campus sites as well as with the NIAID. Core A is responsible for the overall organization, management and
decision making. Core A will provide progress reports to NIAID. Data sharing, acquisition/protection of
intellectual property and involvement of institutional resources are within its purview. This Core will organize
communications, group meetings, teleconferences, presentations and publication of data with rigorous
statistical oversight. Timely submission to NIAID of all abstracts, manuscripts and reviews supported by the
P01 will be through this Core. The allocation of resources to meet various program goals, fiscal prioritization,
responsibilities for resource sharing and information and reagent transmission is an important responsibility.
This Core will also manage a budget for program-related travel and will support a Scientific Advisory Board
(SAB) to evaluate scientific progress and consider pre-clinical efforts moving toward future clinical
development considerations. Core A will oversee the annual SAB meeting in Boston, coordinating travel and
other logistics involving NIAID program staff, SAB and co-investigators attending the meeting. It will organize
an educational component including a seminar series related to structural and molecular approaches to
immunogen design, vaccine delivery in general and RNA vaccines in particular to be co-hosted by Drs.
Reinherz and Weissman.
Relevance
Core A provides overall administrative support, scientific management, and fiscal oversight for the Program.
Additionally, Core A coordinates and fosters interactions among the investigators, collaborators and external
advisors to facilitate the most productive and impactful outcome among the proposed studies.
Terms: <AIDS><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Address><Antigens><Basic Research><Basic Science><Boston><Budgets><Chimera><Chimera organism><Communication><Data><Decision Making><Education><Educational aspects><Ensure><Fostering><Future><Goals><Group Meetings><HIV-1><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human immunodeficiency virus 1><Infection><Institution><Intellectual Property><Investigators><Link><Logistics><Manuscripts><Molecular><NIAID><National Institute of Allergy and Infectious Disease><Non-Polyadenylated RNA><Outcome><Persons><Preventative vaccine><Preventive vaccine><Productivity><Progress Reports><Prophylactic vaccine><Proteins><Protomer><Publications><RNA><RNA Gene Products><RNA vaccine><RNA-based vaccine><Reagent><Research><Research Personnel><Research Resources><Researchers><Resource Allocation><Resource Sharing><Resources><Ribonucleic Acid><Scientific Publication><Series><Site><Structure><Technology><Teleconferences><Transmission><Travel><Vaccines><Viral><biobank><biorepository><chimeras><clinical development><conference><convention><data sharing><deliver vaccines><design><designing><discover vaccines><immunogen><immunogenicity><mRNA vaccine><mRNA-based vaccine><meeting><meetings><multidisciplinary><neutralizing antibody><operation><operations><pre-clinical><preclinical><programs><summit><symposia><symposium><timeline><transmission process><vaccine delivery><vaccine discovery>